For the year ending 2025-12-31, SBFM had -$1,418,971 decrease in cash & cash equivalents over the period. -$5,505,564 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) | -5,975,352 |
| Depreciation and amortization | 332,070 |
| Disposal of tangible assets | 10,257 |
| Stock issued for services | 0 |
| Intangible assets impairment | 1,748,247 |
| Accounts receivable | 116,173 |
| Inventory | 1,637,277 |
| Prepaid expenses | -480,798 |
| Right-of-use asset | -203,836 |
| Accounts payable & accrued expenses | -189,956 |
| Lease liability | -187,523 |
| Earn-out payable | 0 |
| Income tax payable | 0 |
| Net cash flows (used in) operating activities | -5,331,073 |
| Purchase of intangible assets | 661,815 |
| Purchase of equipment | 174,491 |
| Net cash flows (used in) investing activities | -836,306 |
| Proceeds from public offering net (common stock) | 1,828,596 |
| Exercise of warrants | 2,919,812 |
| Purchase of treasury stock | 0 |
| Net cash flows provided by financing activities | 4,748,408 |
| Net (decrease) in cash and cash equivalents | -1,418,971 |
Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc. (SBFM)